Cholesterol-lowering drug can overcome chemotherapy resistance in triple-negative breast cancer, researchers discover

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy. Despite initial responsiveness, many patients experience rapid relapse driven by cancer stem-like cells that survive chemotherapy and seed metastasis.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup